Format

Send to:

Choose Destination
See comment in PubMed Commons below
Can Urol Assoc J. 2013 Jan-Feb;7(1-2 Suppl 1):S5-S10.

Chemotherapy for prostate cancer: Clinical practice in Canada.

Author information

  • 1Chairman, National Cancer Institute of Canada Clinical Trials Genitourinary Group (NCIC-CTG G-U) and Canadian Urologic Oncology Group (CUOG); Professor and Chief of Urology, Director of Urologic Oncology, Endowed Chair in Prostate Cancer, Centre Hospitalier de l'Université de Montréal, Montreal, QC.

Abstract

Whereas prostate cancer was once deemed unresponsive to chemotherapy, there is now evidence that patients with metastatic castration-resistant prostate cancer can obtain a survival benefit from both first-line (docetaxel-based) and second-line (cabazitaxel-based) chemotherapy. The side effects of these agents have been shown to be predictable and manageable, particularly in North American centres. However, patient selection remains a key issue, with the aim of delivering each line of treatment at a time when the individual patient remains fit and well enough to tolerate a cytotoxic regimen. Hence, it is increasingly important for urologists and oncologists to work together to ensure timely consideration of the chemotherapeutic approach before it is precluded by a decline in performance status.

PMID:
23682304
[PubMed]
PMCID:
PMC3652211
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk